Biotech Values

[NP1986]

I only started investing in stocks a couple of months ago, so I bought ARIA when it was in the low 9's (in hindsight, I should've waited a few more weeks). Even if there is a pullback, I'm going to hold on to this stock for at least another year - hopefully longer. I think if everything goes as planned for ponatinib in CML and '113 in EML4-ALK NSCLC, Ariad will be on its way to becoming a multibillion dollar company. Even ignoring any potential new molecules, ponatinib has potential in other cancers. I anticipate that by next year, we'll be seeing investigator-initiated trials of ponatinib in other tumors (probably in combination with approved agents) due to its activity against FGFR. I think the EGFR T790M market will be fairly crowded in a few years' time, so I would consider any of this market share as a bonus for '113.